Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

"Prof. Dr. Silke Laßmann (BSc., PhD.)

Contact

Institut für Klinische Pathologie
Universitätsklinikum Freiburg Breisacher Str. 115a
79106 Freiburg
Tel.: +49 761 270 80620
Fax: +49 761 270-80040
silke.lassmann@uniklinik-freiburg.de
http://www.uniklinik-freiburg.de/pathologie/forschung/ag-lassmann.html

Current Positions

PI Molecular Tumorpathology Research Group
PI Molecular Pathology NGS Routine Diagnostics
Associated Member Excellence Cluster BIOSS II

Research Focus

Molecular Tumorpathology

  • Genetic instability and signalling of GI-tract cancers
  • Epigenetic regulation of GI-tract cancers
  • Molecular mechanisms of targeted therapies (therapy prediction)
  • R&D molecular pathology/molecular diagnostics of FFPE-tissues specimens (e.g. NGS)

DKTK Research Topic

Molecular Diagnostics:

  • Development and Validation of Biromarkers for metastasis (Co-work with Prof. Martin Werner, Dr. Dr. Melanie Börries)
  • Integrated Molecular Diagnostics and advanced clinical application of tumor selected at the Molecuzlar Tumor Board Freiburg (Co-work with Prof. Nikolas von Bubnoff, Dr. Dr. Melanie Börries)

Further Collaborative Projects:

  • 2014: Detection of mutated, free circulating tumor DNA and noncoding RNA in plasma of patients with resectable, stage I-IIIA non-small cell lung cancer (Co-Work with Prof. Nikolas von Bubnoff)

 

Working Group Members DKTK

  • Dipl. Mol. Med. Anna Lena Geißler (PhD-Student)
  • Bianca Riedel (Technician)

Selected Publications

Geißler A-L, Geißler M, Kottmann D, Lutz L, Fichter CD, Fritsch R, Weddeling B, Makowiec F, Werner M, Lassmann S. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. Oncotarget [Internet]. 9. Februar 2017 [zitiert 21. Februar 2017]; Verfügbar unter: www.oncotarget.com/abstract/15211

Lutz L, Fitzner IC, Ahrens T, Geißler A-L, Makowiec F, Hopt UT, Bogatyreva L, Hauschke D, Werner M, Lassmann S. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro. Am J Cancer Res. 2016;6(3):664–76.

Weißer J, Lai ZW, Bronsert P, Kuehs M, Drendel V, Timme S, Kuesters S, Jilg CA, Wellner UF, Lassmann S, Werner M, Biniossek ML, Schilling O. Quantitative proteomic analysis of formalin–fixed, paraffin–embedded clear cell renal cell carcinoma tissue using stable isotopic dimethylation of primary amines. BMC Genomics [Internet]. Dezember 2015 [zitiert 25. August 2015];16(1). Verfügbar unter: www.biomedcentral.com/1471-2164/16/559

Münch C, Dragoi D, Frey A-V, Thurig K, Lübbert M, Wäsch R, Bogatyreva L, Hauschke D, Lassmann S, Werner M, May AM. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research [Internet]. Januar 2015 [zitiert 18. März 2015]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0145212615000247

Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O. Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Molecular Oncology [Internet]. August 2015 [zitiert 6. Oktober 2015]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S1574789115001477

Ahrens TD, Timme S, Ostendorp J, Bogatyreva L, Hoeppner J, Hopt UT, Hauschke D, Werner M, Lassmann S. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity. Lab Invest. 21. Dezember 2015;

Herr R, Köhler M, Andrlova H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N,Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2014 Nov 7. pii: canres.3686.2013. [Epub ahead of print] PubMed PMID: 25381152.

Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A, Köhler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Laßmann S, Wäsch R, Zeiser R. Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. Int J Cancer. 2014 Oct 25. doi: 10.1002/ijc.29289. [Epub ahead of print] PubMed PMID: 25346496.

Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, Maecke HR, Weber WA. Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy? J Nucl Med. 2014 Nov;55(11):1878-84.

Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M, Lassmann S. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.  J Mol Med (Berl). 2014 Aug 6. [Epub ahead of print] PubMed PMID: 25091467.

Rönsch K, Jägle S, Rose K, Seidl M, Baumgartner F, Freihen V, Yousaf A, Metzger E, Lassmann S, Schüle R, Zeiser R, Michoel T, Hecht A. SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer. Mol Oncol. 2014 Sep 16. pii: S1574-7891(14)00213-0. doi: 10.1016/j.molonc.2014.08.016. [Epub ahead of print] PubMed PMID: 25277775.

Bronsert P, Weißer J, Biniossek ML, Kuehs M, Mayer B, Drendel V, Timme S, Shahinian H, Küsters S, Wellner UF, Lassmann S, Werner M, Schilling O. Impact of  routinely employed procedures for tissue processing on the proteomic analysis of  formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl. 2014 Oct;8(9-10):796-804

Vogel T, Lassmann S. Epigenetics: development, dynamics and disease. Cell Tissue Res. 2014 Jun;356(3):451-5. doi: 10.1007/s00441-014-1916-7. PubMed PMID: 24825415.

Ahrens TD, Werner M, Lassmann S. Epigenetics in esophageal cancers. Cell Tissue Res. 2014 Jun;356(3):643-55. doi: 10.1007/s00441-014-1876-y. Epub 2014 May 10. PubMed PMID: 24816987.

Jägle S, Rönsch K, Timme S, Andrlová H, Bertrand M, Jäger M, Proske A, Schrempp M, Yousaf A, Michoel T, Zeiser R, Werner M, Lassmann S, Hecht A. Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4886-91.

Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S. EGFR,  HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer. 2014 Oct 1;135(7):1517-30.

May AM, Frey AV, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lübbert M, Wäsch R, Werner M, Hasskarl J, Lassmann S. ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes. Histochem Cell Biol. 2014 Apr;141(4):431-40.

 

-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de

Dr. Anna Dost
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 77121
a.dost@dkfz-heidelberg.de